Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction

BACKGROUND: The epidermal growth factor receptor (EGFR) inhibitor, gefitinib, has been reported to successfully treat advanced non-small cell lung cancer patients with genetic mutations in EGFR. The aim of this study was to investigate the existence of EGFR mutations in carcinoma of esophagogastric...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wen-Ping, Wang, Kang-Ning, Gao, Qiang, Chen, Long-Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278359/
https://www.ncbi.nlm.nih.gov/pubmed/22252115
http://dx.doi.org/10.1186/1477-7819-10-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278359/
https://www.ncbi.nlm.nih.gov/pubmed/22252115
http://dx.doi.org/10.1186/1477-7819-10-14

Ejemplares similares